• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clearside Biomedical

Clearside Biomedical prices $36m IPO

December 9, 2016 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) today priced its $36 million initial public offering, floating 4 million shares at $9 apiece and including a 30-day underwriters option for 600,000 more shares. Alpharetta, Ga.-based Clearside said it plans to use theIPO proceeds to fund a pivotal Phase III trial of its suspension formulation of corticosteroid triamcinolone acetonide, Zuprata, for […]

Filed Under: Featured, Initial Public Offering (IPO), Optical/Ophthalmic, Wall Street Beat Tagged With: Clearside Biomedical

Clearside Biomedical launches trial for Zuprata

November 15, 2016 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in clinical trial of its suspension formulation of corticosteroid triamcinolone acetonide, Zuprata, for the treatment of diabetic macular edema. The Alpharetta, Ga.-based company’s Hulk Phase I/II trial is an open-label, multi-center study designed to evaluate the safety and efficacy Zuprata administered in the suprachoroidal space […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Clearside Biomedical

Clearside tops Q3 estimates, posts license revenue

November 9, 2016 By Sarah Faulkner

Clearside Biomedical

Shares in Clearside Biomedical (NSDQ:CLSD) rose today after the biopharmaceutical company met expectations on Wall Street with its 3rd quarter results. The Alpharetta, Ga.-based company posted losses of -$5.6 million, or -28¢ per share, on sales of $5,000 for the 3 months ended Sept. 30. This is the 1st quarter that Clearside has reported revenue. Adjusted to exclude […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic Tagged With: Clearside Biomedical

Clearside Biomedical names McElheny as biz dev veep | Personnel Moves, Nov. 8, 2016

November 8, 2016 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) today named Rick McElheny as its VP of business development. The Alpharetta, Ga.-based company is developing a microinjector loaded with CLS-TA (triamcinolone acetonide) to treat macular edema. The device is designed to inject the compound in the a 30-µm gap between the choroid and the sclera, called the suprachoroidal space. A pivotal Phase III […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Personnel Tagged With: Clearside Biomedical, johnsonandjohnson

Clearside Biomedical floats $50m IPO

June 2, 2016 By Brad Perriello

Clearside Biomedical raised $50 million with its initial public offering, floating 7.2 million shares at $7 apiece. That’s below the range Clearside earlier set for the IPO, when it planned to put up 4.0 million shares at a range of $14 to $16, for a midpoint value of $60 million. Alpharetta, Ga.-based Clearside is developing a drug-device combination to treat […]

Filed Under: Drug-Device Combinations Tagged With: Clearside Biomedical

Clearside Biomedical raises $14.4m, enrolls 1st patient in Phase III trial

December 8, 2015 By Fink Densford

Clearside Biomedical raised $14.4 million in a new round of equity financing, and said yesterday it enrolled the 1st patient in the Phase 3 Peachtree clinical trial of its CLS-TA for treating patients with macular edema associated with non-infectious uveitis. Clearside is developing CLS-TA triamcinolone acetonide to be delivered using its proprietary SCS microinjector for patients with […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations Tagged With: Clearside Biomedical

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS